author-photo

P. Brunsvig

Oslo University Hospital

5

Papers

26

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

P1.01-72 A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis

2019
Show All
- Source
- Cite
- Save
Citations (0)
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin

2015 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (25)